MedCity News November 24, 2024
Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions.
Halozyme has withdrawn its offer to buy biopharmaceutical services firm Evotec for €2 billion, a move that comes after repeated requests to meet with the company to discuss a deal were all turned down.
Halozyme, a company with a platform technology for delivering biologic drugs, revealed its acquisition offer earlier in November. But the San Diego-based company said Friday that the months prior to publicly announcing a bid were spent conducting diligence on its proposal, including informal discussions with one member of Evotec’s supervisory board. That’s as far as any...
Today's Sponsors
Today's Sponsor